

## Advances in CKD Detection and Determination of Prognosis: Executive Summary of the National Kidney Foundation–Kidney Early Evaluation Program (KEEP) 2012 Annual Data Report

Adam T. Whaley-Connell, DO, MSPH,<sup>1</sup> Manjula Kurella Tamura, MD, MPH,<sup>2</sup>  
Claudine T. Jurkowitz, MD, MPH,<sup>3</sup> Mikhail Kosiborod, MD,<sup>4</sup> and  
Peter A. McCullough, MD, MPH<sup>5,6,7</sup>

During 2012, the National Kidney Foundation (NKF)–Kidney Early Evaluation Program (KEEP) continued its efforts toward early detection of chronic kidney disease (CKD) in populations at high risk of kidney disease and toward improving awareness of CKD across the globe. Through the completely volunteer participation of the nephrology community, including physicians and our allied health care partners, KEEP continues to screen volunteer participants as part of a national effort to detect and track CKD. In 2012, we observed some changes in the CKD landscape, including questions regarding the utility of CKD screening and detection strategies from the US Preventive Services Task Force.<sup>1</sup> Through the years, data derived from KEEP have provided important observations regarding detection and risk-stratification strategies using estimated glomerular filtration rate (eGFR) and proteinuria.<sup>2–4</sup> In this past year, KEEP provided new information on topics including blood pressure control, disorders of mineral metabolism, and awareness of CKD and access to health care as related to CKD outcomes.<sup>5–11</sup> In this supplement to *AJKD*, we focus on the variable nature of CKD progression. Interest is increasing in exploring factors that influence disease progression beyond traditional measures, such as blood pressure and glycemic control, and in determining the contribution of socioeconomic factors.<sup>12,13</sup> We present 3 articles highlighting factors that influence disease progression in KEEP participants: (1) Chang et al<sup>14</sup> describe risk factors for progression to end-stage renal disease (ESRD) among KEEP participants with preserved eGFR at screening, with and without albuminuria; (2) Amin et al<sup>15</sup> report on whether synergism in using eGFR and albuminuria enhances risk prediction for death and disease progression; and (3) Jurkowitz et al<sup>16</sup> report on insurance status as a risk factor for disease progression.

### UNDERSTANDING RISK FOR PROGRESSION IN SCREENED PARTICIPANTS WITH PRESERVED ESTIMATED GFR

The present knowledge regarding disease progression has been defined by studies that explore factors such as hypertension, diabetes, and ethnicity, primarily in patients with already moderately decreased eGFR. How-

ever, there are few data for risk factors that influence progression in populations with preserved eGFR (ie, >60 mL/min/1.73 m<sup>2</sup>). Available evidence in this rather unique population is limited due to the relatively large sample sizes and long follow-up time needed to accrue ESRD cases. KEEP provides a unique opportunity to explore risk factors for disease progression in a large screened cohort of participants at high risk of early-stage CKD. Chang et al<sup>14</sup> stratify participants by the presence or not of albuminuria and demonstrate that black race, diabetes mellitus, lower eGFR, and higher systolic blood pressure are associated with developing ESRD irrespective of albuminuria status (absolute magnitude of risk was higher for participants with albuminuria). Results from this study would suggest that screening for albuminuria in people with ESRD risk factors could aid in prognostication.

### DOES USE OF ESTIMATED GFR AND ALBUMINURIA ENHANCE RISK PREDICTION?

An emerging subset of patients in population-based studies of CKD do not have proteinuria, but show progressively decreasing eGFR. Prior studies using KEEP and NHANES (National Health and Nutrition Examination Survey) data suggest that only a minority of participants experience both decreased eGFR

---


From the <sup>1</sup>Harry S. Truman Memorial Veterans Hospital, Department of Medicine, Division of Nephrology and Hypertension, University of Missouri–Columbia School of Medicine, Columbia, MO; <sup>2</sup>Geriatric Research and Education Clinical Center, Veterans Affairs Palo Alto, Palo Alto, CA; <sup>3</sup>Christiana Care Center for Outcomes Research, Christiana Care Health System, Newark, DE; <sup>4</sup>Saint Luke's Mid America Heart Institute and University of Missouri, Kansas City, MO; and <sup>5</sup>St. John Providence Health System, Warren; <sup>6</sup>St. John Hospital and Medical Center, Detroit; and <sup>7</sup>Providence Hospitals and Medical Centers, Southfield and Novi, MI.

Address correspondence to Adam Whaley-Connell, DO, MSPH, Harry S. Truman Memorial Veterans Hospital and the University of Missouri–Columbia School of Medicine, Department of Internal Medicine, Division of Nephrology and Hypertension, 800 Hospital Dr, Columbia, MO 65201. E-mail: whaleyconnella@health.missouri.edu

Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc. This is a US Government Work. There are no restrictions on its use.

0272-6386/\$0.00

<http://dx.doi.org/10.1053/j.ajkd.2013.01.006>



**Figure 1.** Detection of chronic kidney disease (CKD) as a function of age and measurement of estimated glomerular filtration rate (eGFR) and urine albumin-creatinine ratio (ACR) in the same patients. Relative proportions of ACR  $\geq 30$  mg/g, eGFR  $< 60$  mL/min/1.73 m<sup>2</sup>, and both as positive screening tests for CKD in KEEP (Kidney Early Evaluation Program) and NHANES (National Health and Nutrition Examination Survey) 1999-2004.  $P < 0.001$  for eGFR and ACR trend. Reproduced from McCullough et al<sup>17</sup> with permission of the National Kidney Foundation.

and albuminuria (Fig 1),<sup>17</sup> including participants with diabetes. When considering detection of diabetic kidney disease, the presence of proteinuria varies widely relative to eGFR decrease and age; thus, KEEP data provide a unique opportunity to explore whether detecting CKD using both proteinuria and eGFR improves risk prediction in diabetic participants. Amin et al<sup>15</sup> observe that levels of albuminuria and eGFR may be discordant. Fourteen percent of participants with low eGFR had no albuminuria, whereas 12% of participants who had albuminuria did not have decreased eGFR. Consistent with the present knowledge regarding decreased eGFR and the presence of albuminuria in CKD, both factors predicted mortality and progression to ESRD. A key novel observation was a highly significant interaction between lower eGFR and greater degree of albuminuria, such that the presence of both factors amplified the risk of mortality and progression to ESRD beyond what would be expected by the simple combination of their independent effects. Interestingly, the authors also report that albuminuria was a stronger predictor of mortality and decreased eGFR was a stronger predictor of progression to ESRD. These data suggest that using both eGFR and albuminuria might improve risk prediction for CKD-related outcomes.

### INSURANCE STATUS AND RISK OF DEATH AND ESRD


Jurkovitz et al<sup>16</sup> explore whether health insurance status affects CKD-related outcomes. Studies of the general population suggest that lack of insurance is associated with higher mortality rates, and patients who

have insurance are more likely to have controlled blood pressure and diabetes. Uninsured patients with CKD are less likely to receive appropriate risk-factor interventions.<sup>18</sup> However, the impact of insurance status in a screened population as it relates to disease progression and mortality is unknown. Jurkovitz et al<sup>16</sup> characterize the burden of disease in KEEP participants without insurance and report time to ESRD and death in participants with and without insurance. Interestingly, uninsured KEEP participants were 82% more likely to die and 72% more likely to progress to ESRD than their insured counterparts, a significant finding that remained after clinical adjustments. Considering the morbidity, mortality, and increasing costs associated with CKD, ensuring access to appropriate care and insurance coverage for patients with CKD would seem essential for optimal outcomes. This study is particularly timely with regard to the controversial issues of health care reform, and the data support the view that expansion of health care coverage to more individuals may, at least in the case of early detection of progressive CKD, promote improved outcomes and decreased costs.

### SUMMARY

NKF-KEEP has been the only sustained chronic disease screening, detection, and awareness program in the United States. Its success should be attributed to the renal community and to a detection method that places a premium on patient care. Understanding of barriers to care and factors that influence disease progression in early CKD stages is limited, but crucial to improving CKD-related morbidity and mortality. KEEP data provide unique opportunities for the renal community to increase understanding of the role of detection on a large scale as related to variable CKD progression (Fig 2), related complications, and mortality. In 2012, data derived from KEEP continued to provide important information regarding CKD complications, such as control of blood pressure and mineral metabolism, and regarding awareness and access issues.<sup>5-11</sup> In this supplement, we report factors that influence disease progression in high-risk participants with preserved eGFR,<sup>14</sup> whether combined use of eGFR and albuminuria enhances risk prediction,<sup>15</sup> and the role of insurance status.<sup>16</sup>

The KEEP steering committee continues to develop novel methods to reach patients and providers, expand understanding of barriers to care, and increase CKD awareness and general measures to improve disease-related morbidity. We anticipate that future work also will improve the complex interface between disease detection, navigation of the health care system, and CKD-related outcomes. Of greatest importance will be movement toward enhanced scalability of KEEP to achieve even greater reach across the United States and in partnership with primary care physicians, spe-



**Figure 2.** The role for detection of chronic kidney disease (CKD) in earlier stages to allow sufficient time for risk-factor reduction to reduce CKD-related complications and progression to renal replacement therapy. Abbreviations: ACR, albumin-creatinine ratio; eGFR, estimated glomerular filtration rate.

cialists, and our international colleagues around the world. This inflection point in the history of KEEP is important as the program moves from site-driven screening events to more global internet-based self-reported data, advanced kidney learning systems, and clinical involvement from practicing physicians caring for individuals at risk for CKD and ESRD.

## ACKNOWLEDGEMENTS

**Support:** KEEP is a program of the NKF and is supported by Abbott, Amgen, LifeScan, Siemens, Genentech, GM Foundation, Nephroceuticals, and Pfizer.

**Financial Disclosure:** Dr Kosiborod is a consultant for Medtronic Diabetes, Genentech, Hoffman La Roche, Gilead, Glumetrics, Boehringer-Ingelheim, and Kowa Pharmaceuticals. The other authors declare that they have no other relevant financial interests.

## REFERENCES

1. Moyer VA. Screening for chronic kidney disease: US Preventive Services Task Force recommendation statement. *Ann Intern Med.* 2012;157(8):567-570.
2. Stevens LA, Li S, Kurella Tamura M, et al. Comparison of the Chronic Kidney Disease Epidemiology Collaboration and Modification of Diet in Renal Disease Study glomerular filtration rate estimating equations for determining chronic kidney disease prevalence, risk factors and mortality in the Kidney Early Evaluation Program. *Am J Kidney Dis.* 2011;57(suppl 2):S9-S16.
3. Whaley-Connell AT, Sowers JR, Stevens LA, et al; Kidney Early Evaluation Program Investigators. CKD in the United States: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES) 1999-2004. *Am J Kidney Dis.* 2008;51(suppl 2):S13-S20.
4. McCullough PA, Jurkovitz CT, Pergola PE, et al; for the KEEP Investigators. Independent components of chronic kidney

disease as a cardiovascular risk state: results from the Kidney Early Evaluation Program (KEEP). *Arch Intern Med.* 2007;167(11):1122-1129.

5. Peralta CA, Norris KC, Li S, et al. Blood pressure components and end-stage renal disease in persons with chronic kidney disease: the Kidney Early Evaluation Program (KEEP). *Arch Intern Med.* 2012;172(1):41-47.

6. Whaley-Connell A, Shlipak MG, Inker LA, et al; Kidney Early Evaluation Program Investigators. Awareness of kidney disease and relationship to end-stage renal disease and mortality. *Am J Med.* 2012;125(7):661-669.

7. Saab G, Bombback AS, McFarlane SI, et al; for the Kidney Early Evaluation Program Investigators. The association of parathyroid hormone with ESRD and pre-ESRD mortality in the Kidney Early Evaluation Program. *J Clin Endocrinol Metab.* 2012;97(12):4414-4421.

8. Agrawal V, Jaar BG, Frisby XY, et al. Access to health care among adults evaluated for CKD: findings from the Kidney Early Evaluation Program (KEEP). *Am J Kidney Dis.* 2012;59(suppl 2):S5-S15.

9. Shah A, Fried LF, Chen SC, et al. Associations between access to care and awareness of CKD. *Am J Kidney Dis.* 2012;59(suppl 2):S16-S23.

10. Jurkovitz CT, Elliott D, Li S, et al. Physician utilization, risk-factor control, and CKD progression among participants in the Kidney Early Evaluation Program (KEEP). *Am J Kidney Dis.* 2012;59(suppl 2):S24-S33.

11. Saab G, Chen SC, Li S, et al. Association of physician care with mortality in Kidney Early Evaluation Program (KEEP) participants. *Am J Kidney Dis.* 2012;59(suppl 2):S34-S39.

12. Jafar TH, Stark PC, Schmid CH, et al; AIPRD Study Group. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. *Ann Intern Med.* 2003;139(4):244-252.

13. Hsu CY, McCulloch CE, Darbinian J, Go AS, Iribarren C. Elevated blood pressure and risk of end-stage renal disease in subjects without baseline kidney disease. *Arch Intern Med.* 2005;165(8):923-928.

14. Chang TI, Li S, Chen SC, et al. Risk factors for ESRD in individuals with preserved estimated GFR with and without albuminuria: results from the Kidney Early Evaluation Program (KEEP). *Am J Kidney Dis.* 2013;61(4)(suppl 2):S4-S11.

15. Amin AP, Whaley-Connell AT, Li S, Chen SC, McCullough PA, Kosiborod MN. The synergistic relationship between estimated GFR and microalbuminuria in predicting long-term progression to ESRD or death in patients with diabetes: results from the Kidney Early Evaluation Program (KEEP). *Am J Kidney Dis.* 2013;61(4)(suppl 2):S12-S23.

16. Jurkovitz CT, Li S, Norris KC, et al. Association between lack of health insurance and risk of death and ESRD: results from the Kidney Early Evaluation Program (KEEP). *Am J Kidney Dis.* 2013;61(4)(suppl 2):S24-S32.

17. McCullough PA, Li S, Jurkovitz CT, et al; on behalf of the Kidney Early Evaluation Program Investigators. CKD and cardiovascular disease in screened high-risk volunteer and general populations: the Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES) 1999-2004. *Am J Kidney Dis.* 2008;51(suppl 2):S38-S45.

18. Hall YN, Rodriguez RA, Boyko EJ, Chertow GM, O'Hare AM. Characteristics of uninsured Americans with chronic kidney disease. *J Gen Intern Med.* 2009;24(8):917-922.